接上篇 天坛小儿神外宫剑访谈（上篇）-儿童颅咽管瘤经前纵裂入路手术难度分型及热点问题探讨

7、前纵裂入路最大的障碍是前交通动脉，有学者提出主动切断以增加术腔显露，请问您的观点？

前交通动脉直接影响前纵裂入路术野的暴露，无论经第I间隙还是第IV间隙切除肿瘤，前交通动脉的宽度直接限制了额叶牵拉和肿瘤的侧方暴露。理论上，前交通动脉平均长度可达12.7mm，有足够的活动度与延展性[50]，但临床中不少病例由于前交通动脉短粗，严重影响了暴露范围。因此，有些学者提出主动切断前交通动脉换取更加宽阔的手术空间[51]。我们主张应保护好前交通动脉，通过锐性松解蛛网膜，达到最佳暴露效果[50]。损伤前交通动脉孤立了双侧大脑前动脉，增加了大脑前动脉梗塞的风险（图8）[52]。另外，前交通动脉发出重要的前穿质（下丘脑支、视交叉支、胼胝体下动脉），损伤后可能导致穹隆、胼胝体膝部梗塞[53]，表现为顺行性失忆、执行功能障碍、性格改变等“前交通动脉综合征”[54]。

图8：儿童颅咽管瘤手术一例，术中前交通动脉损伤，术后双侧额叶大面积梗塞。虽属罕见，一旦出现，预后极差。

需要特别指出，任何经前纵裂手术都要做好前交通动脉破裂出血的应急预案，特别是婴幼儿，瞬间急性失血危及生命。我们每年经前纵裂入路切除鞍区肿瘤近200例（颅咽管瘤、视路胶质瘤、鞍区生殖细胞类肿瘤等），术中前交通动脉破裂出血概率1-2%，多因肿瘤囊壁与动脉粘连紧密甚至侵蚀，一经游离即管壁破裂，出血凶猛。此时，术者要沉着冷静，与时间赛跑，吸引器准确指向破裂口，防止血液倒灌至深方造成急性脑膨出；助手可以夹住破口，降低流速，此时，术者无论电凝烧灼或动脉瘤夹夹闭（图9），一定要确切止血，切记不要海绵压迫[55,56]或采取肌肉粘附破裂口[57]；一旦迟发出血，患儿瞬间昏迷，严重者危及生命，我们曾有血的教训，在此提醒同行切记。

图9： 本例游离肿瘤顶壁与前交通动脉粘连处时，突然破裂出血、瞬时凶猛，两枚蛇牌720动脉瘤夹夹闭，确切止血。

8、颅咽管瘤复发率高，一旦复发就要再次手术吗？请谈谈您的观点。

颅咽管瘤是良性肿瘤，恶性生长。其侵袭性生长方式，类似于恶性肿瘤，极易复发[19]。一旦颅咽管瘤术后复发，是再次手术还是采取其它治疗方式？由于复发颅咽管瘤已失去瘤体与下丘脑正常界面，手术风险大大提高[59，此时，医生的经验起到决定性作用。他必须准确预判，再次手术和其它治疗，哪种方式对患儿更安全，更有效。若经验不足，一念之差就决定了患儿的生死，一定要慎重抉择。目前除手术外，针对复发颅咽管瘤，应用最广的是伽玛刀治疗，特别适用于术后残留或复发的实体小肿瘤；对于体积较大的囊性肿瘤，可抽吸缩小后再行伽玛刀治疗，肿瘤控制率可达88.5%[58]；针对瘤体囊性变采取囊内放射性治疗（32P，90Yu，186Rh和198Au）、博来霉素治疗、IFN-α治疗，10年有效控制率达80%以上[59]。因此，针对复发颅咽管瘤要制定个体化治疗方案，降低致残致死率（图10）。

图10：8岁男性患儿，主诉：间断头痛2年余，多饮多尿2周。头颅CT示鞍区类圆形钙化影；MRI示鞍内、鞍上囊实性混杂信号，大小约45×28×19mm,不均匀强化，颅咽管瘤诊断明确（上排）。2015年8月行前纵裂入路肿瘤切除术，肿瘤切除满意，术后下丘脑反应轻、恢复好，定期随访。术后2年，发现鞍上囊性变，考虑肿瘤复发，鉴于复发肿瘤体积小、位置深在、囊性为主，再次手术风险大，改行立体定向囊腔穿刺囊液抽吸+伽玛刀治疗。随访至今，肿瘤控制满意，未见生长。目前，术后六年，患儿身高增长近50cm, 正常学习生活,笔者甚感欣慰。

9、颅咽管瘤术后，由于患儿身材矮小，家长急于要求注射生长激素，您的建议？

颅咽管瘤患儿术后生长激素缺乏高达75%[60]，表现为身材矮小、性发育迟缓，家长迫切希望通过注射生长激素促进孩子身高增长。但是，需要特别关注，生长激素具有促进细胞有丝分裂及抗凋亡作用，不但对正常组织有增殖效应，对肿瘤的生长、转移也有促进作用[61]。因此，生长激素可以明确促使颅咽管瘤复发，年龄越小，复发率越高[62]。颅咽管瘤术后患儿，一定要谨慎，不应人为促进肿瘤复发。何时注射，应选择对肿瘤复发影响最小的时机。我们与北京儿童医院内分泌科多年合作，一致建议颅咽管瘤术后经过5年随访，没有肿瘤复发迹象后再使用生长激素，可将复发率降至最低。

参考文献：

[1] Perry A L D, Von Deimling a, Sahm F, Rushing Ej, Mawrin C, Et Al. Meningiomas. In: Louis Dn, Ohgaki H, Wiestler Od, Cavenee Wk, Ellison Dw, Figarella-Branger D.WHO Classification of Tumors of the Central Nervous System.[J].Lyon: International Agency on Cancer Research,2016.

[2] Louis D N, Perry A, Wesseling P, et al.The 2021 WHO Classification of Tumors of the Central Nervous System: a summary[J].Neuro Oncol,2021.

[3] Hölsken A, Sill M, Merkle J, et al.Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles[J].Acta Neuropathol Commun,2016, 4: 20.

[4] Feng Y, Ni M, Wang Y G, et al.Comparison of neuroendocrine dysfunction in patients with adamantinomatous and papillary craniopharyngiomas[J].Exp Ther Med,2019, 17 (1): 51-56.

[5] 邹扬帆, 宁浩勇, 于新.颅咽管瘤的病理特征及分子病理学研究进展[J].中国临床神经外科杂志,2020 (06): 403-406.

[6] Müller H L, Merchant T E, Warmuth-Metz M, et al.Craniopharyngioma[J].Nat Rev Dis Primers,2019, 5 (1): 75.

[7] Tariq M U, Din N U, Ahmad Z, et al.Papillary craniopharyngioma: A clinicopathologic study of a rare entity from a major tertiary care center in Pakistan[J].Neurol India,2017, 65 (3): 570-576.

[8] Pekmezci M, Louie J, Gupta N, et al.Clinicopathological characteristics of adamantinomatous and papillary craniopharyngiomas: University of California, San Francisco experience 1985-2005[J].Neurosurgery,2010, 67 (5): 1341-9; discussion 1349.

[9] Patel V S, Thamboo A, Quon J, et al.Outcomes After Endoscopic Endonasal Resection of Craniopharyngiomas in the Pediatric Population[J].World Neurosurg,2017, 108: 6-14.

[10] Pan J, Qi S, Liu Y, et al.Growth patterns of craniopharyngiomas: clinical analysis of 226 patients[J].J Neurosurg Pediatr,2016, 17 (4): 418-33.

[11] Puget S, Garnett M, Wray A, et al.Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement[J].J Neurosurg,2007, 106 (1 Suppl): 3-12.

[12] Apra C, Enachescu C, Lapras V, et al.Is Gross Total Resection Reasonable in Adults with Craniopharyngiomas with Hypothalamic Involvement?[J].World Neurosurg,2019, 129: e803-e811.

[13] Müller H L.Hypothalamic involvement in craniopharyngioma-Implications for surgical, radiooncological, and molecularly targeted treatment strategies[J].Pediatr Blood Cancer,2018, 65 (5): e26936.

[14] Dho Y-S, Kim Y H, Se Y-B, et al.Endoscopic endonasal approach for craniopharyngioma: the importance of the relationship between pituitary stalk and tumor[J].Journal of Neurosurgery JNS,2018, 129 (3): 611-619.

[15] Pereira A M, Schmid E M, Schutte P J, et al.High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma[J].Clin Endocrinol (Oxf),2005, 62 (2): 197-204.

[16] Mazzatenta D, Zoli M, Guaraldi F, et al.Outcome of Endoscopic Endonasal Surgery in Pediatric Craniopharyngiomas[J].World Neurosurg,2020, 134: e277-e288.

[17] Koutourousiou M, Gardner P A, Fernandez-Miranda J C, et al.Endoscopic endonasal surgery for craniopharyngiomas: surgical outcome in 64 patients[J].J Neurosurg,2013, 119 (5): 1194-207.

[18] Park H J, Dho Y S, Kim J H, et al.Recurrence Rate and Prognostic Factors for the Adult Craniopharyngiomas in Long-Term Follow-Up[J].World Neurosurg,2020, 133: e211-e217.

[19] Gupta D K, Ojha B K, Sarkar C, et al.Recurrence in pediatric craniopharyngiomas: analysis of clinical and histological features[J].Childs Nerv Syst,2006, 22 (1): 50-5.

[20] Erfurth E M, Holmer H, Fjalldal S B.Mortality and morbidity in adult craniopharyngioma[J].Pituitary,2013, 16 (1): 46-55.

[21] Fujio S, Hanada T, Yonenaga M, et al.Surgical aspects in craniopharyngioma treatment[J].Innovative Surgical Sciences,2021, 6 (1): 25-33.

[22] Coppens J R, Couldwell W T.Staged Use of the Transsphenoidal Approach to Resect Superior Third Ventricular Craniopharyngiomas[J].Minim Invasive Neurosurg,2010, 53 (01): 40-43.

[23] Yang I, Sughrue M E, Rutkowski M J, et al.Craniopharyngioma: a comparison of tumor control with various treatment strategies[J].Neurosurg Focus,2010, 28 (4): E5.

[24] Zhu W, Li X, He J, et al.A reformed surgical treatment modality for children with giant cystic craniopharyngioma[J].Childs Nerv Syst,2017, 33 (9): 1491-1500.

[25] 宫剑.宫剑教授病例分享（六）：婴幼儿巨大颅咽管瘤的治疗体会[J].“宫剑”WX号,2020.

[26] Marcus H J, Rasul F T, Hussein Z, et al.Craniopharyngioma in children: trends from a third consecutive single-center cohort study[J].J Neurosurg Pediatr,2019: 1-9.

[27] Soleman J, Ber R, Constantini S, et al.The interhemispheric approach in children: our experience and review of the literature[J].Childs Nerv Syst,2019, 35 (3): 445-452.

[28] Feng S-Y, Zhang Y-Y, Yu X-G, et al.Microsurgical treatment of craniopharyngioma: Experiences on 183 consecutive patients[J].Medicine,2018, 97 (34): e11746.

[29] Altay T, Couldwell W T.The frontotemporal (pterional) approach: an historical perspective[J].Neurosurgery,2012, 71 (2): 481-91; discussion 491-2.

[30] Yaşargil M G, Curcic M, Kis M, et al.Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients[J].J Neurosurg,1990, 73 (1): 3-11.

[31] Yasargil M G.Microneurosurgery of CNS tumors[J],1996.

[32] Iancu C. Advances in Endoscopic Surgery[M].France: InTech,2011.

[33] Bajaj J, Chandra P S.Recent Developments in Endoscopic Endonasal Approach for Pituitary Adenomas[J].Neurol India,2020, 68 (Supplement): S79-s84.

[34] 神经内镜经鼻颅咽管瘤切除技术专家共识[J].中华神经外科杂志,2020, 36 (11): 1088-1095.

[35] Soldozy S, Yeghyayan M, Yağmurlu K, et al.Endoscopic endonasal surgery outcomes for pediatric craniopharyngioma: a systematic review[J].Neurosurg Focus,2020, 48 (1): E6.

[36] Kobets A, Ammar A, Dowling K, et al.The limits of endoscopic endonasal approaches in young children: a review[J].Childs Nerv Syst,2020, 36 (2): 263-271.

[37] Tatreau J R, Patel M R, Shah R N, et al.Anatomical considerations for endoscopic endonasal skull base surgery in pediatric patients[J].Laryngoscope,2010, 120 (9): 1730-7.

[38] Tatreau J R, Patel M R, Shah R N, et al.Anatomical limitations for endoscopic endonasal skull base surgery in pediatric patients[J].Laryngoscope,2010, 120 Suppl 4: S229.

[39] Koutourousiou M, Fernandez-Miranda J C, Wang E W, et al.The limits of transsellar/transtuberculum surgery for craniopharyngioma[J].J Neurosurg Sci,2018, 62 (3): 301-309.

[40] Kasemsiri P, Carrau R L, Prevedello D M, et al.Indications and limitations of endoscopic skull base surgery[J].Future Neurology,2012, 7 (3): 263-277.

[41] Snyderman C H, Pant H, Carrau R L, et al.What are the limits of endoscopic sinus surgery?: the expanded endonasal approach to the skull base[J].Keio J Med,2009, 58 (3): 152-60.

[42] Samii M, Tatagiba M.Surgical management of craniopharyngiomas: a review[J].Neurol Med Chir (Tokyo),1997, 37 (2): 141-9.

[43] Kassam A B, Gardner P A, Snyderman C H, et al.Expanded endonasal approach, a fully endoscopic transnasal approach for the resection of midline suprasellar craniopharyngiomas: a new classification based on the infundibulum[J].J Neurosurg,2008, 108 (4): 715-28.

[44] Qi S, Lu Y, Pan J, et al.Anatomic relations of the arachnoidea around the pituitary stalk: relevance for surgical removal of craniopharyngiomas[J].Acta Neurochir (Wien),2011, 153 (4): 785-96.

[45] Tang B, Xie S H, Xiao L M, et al.A novel endoscopic classification for craniopharyngioma based on its origin[J].Scientific Reports,2018, 8 (1): 10215.

[46] Jung T Y, Jung S, Moon K S, et al.Endocrinological outcomes of pediatric craniopharyngiomas with anatomical pituitary stalk preservation: preliminary study[J].Pediatr Neurosurg,2010, 46 (3): 205-12.

[47] Xiao G, Yuan X, Yuan J, et al.Pituitary stalk management during the microsurgery of craniopharyngiomas[J].Exp Ther Med,2014, 7 (5): 1055-1064.

[48] Ordóñez-Rubiano E G, Forbes J A, Morgenstern P F, et al.Preserve or sacrifice the stalk? Endocrinological outcomes, extent of resection, and recurrence rates following endoscopic endonasal resection of craniopharyngiomas[J].J Neurosurg,2018: 1-9.

[49] Fujisawa I, Kikuchi K, Nishimura K, et al.Transection of the pituitary stalk: development of an ectopic posterior lobe assessed with MR imaging[J].Radiology,1987, 165 (2): 487-9.

[50] Mortini P, Gagliardi F, Boari N, et al.The combined interhemispheric subcommissural translaminaterminalis approach for large craniopharyngiomas[J].World Neurosurg,2013, 80 (1-2): 160-6.

[51] Shibuya M, Takayasu M, Suzuki Y, et al.Bifrontal basal interhemispheric approach to craniopharyngioma resection with or without division of the anterior communicating artery[J].J Neurosurg,1996, 84 (6): 951-6.

[52] Sousa C S M D, Miranda C L V M D, Avelino M C, et al.Thrombosis of the Azygos Anterior Cerebral Artery[J].Case Reports in Radiology,2017, 2017: 5409430.

[53] Meila D, Saliou G, Krings T.Subcallosal artery stroke: infarction of the fornix and the genu of the corpus callosum. The importance of the anterior communicating artery complex. Case series and review of the literature[J].Neuroradiology,2015, 57 (1): 41-7.

[54] Molino I, Cavaliere C, Salvatore E, et al.Is Anterior Communicating Artery Syndrome Related to Fornix Lesions?[J].Journal of Alzheimer's Disease,2014, 42: S199-S204.

[55] Foundation A.Management of Surgical Hemostasis-Independent Study Guide[J],2013.

[56] Freeman J L, Winston K R, Byers J T, et al.Damage-control neurosurgery: Packing to halt relentless intracranial bleeding[J].Journal of Trauma and Acute Care Surgery,2015, 79 (5): 865-869.

[57] Chivukula S, Weiner G M, Engh J A.The early days of hemostasis in neurosurgery[J].Neurosurg Focus,2014, 36 (4): E5.

[58] Saleem M A, Hashim A S, Rashid A, et al.Role of gamma knife radiosurgery in multimodality management of craniopharyngioma[J].Acta Neurochir Suppl,2013, 116: 55-60.

[59] Yu X, Christ S M, Liu R, et al.Evaluation of Long-Term Outcomes and Toxicity After Stereotactic Phosphorus-32-Based Intracavitary Brachytherapy in Patients With Cystic Craniopharyngioma[J].Int J Radiat Oncol Biol Phys,2021.

[60] Müller H L.Childhood Craniopharyngioma[J].Hormone Research in Paediatrics,2008, 69 (4): 193-202.

[61] Barabutis N, Schally A V.Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines[J].Br J Cancer,2008, 98 (11): 1790-6.

[62] Smith T R, Cote D J, Jane J A, Jr., et al.Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study[J].J Neurosurg Pediatr,2016, 18 (4): 408-412.